CCHT(SZ:000661)2022-12-07 08:31Financial Performance - The company achieved a revenue of 1.07 billion CNY in the first half of the year, representing a year-on-year growth of 22.62% [3] - The net profit attributable to shareholders was 170 million CNY, with a year-on-year increase of 62.27% [3] - The pharmaceutical segment generated 860 million CNY in revenue, growing by 4.99%, and net profit of 150 million CNY, up by 16.39% [3] Product Development and Market Strategy - JinSai Pharmaceutical's net profit reached 180 million CNY, marking a 15.11% increase [3] - The GMP certification for follicle-stimulating hormone has been announced, allowing for official production and sales [4] - The company is exploring a marketing model through the establishment of Shanghai Tongxin Hospital Management Company to enhance competitive positioning [4][5] Market Trends and Challenges - The pharmaceutical industry is facing challenges due to mandatory price reductions and regulatory constraints from public hospital procurement [3] - The sales growth of the pharmaceutical segment is showing signs of slowing down due to external and internal factors [3] Future Outlook and Innovations - The company is focusing on the development of thymosin α1 and other potential products, with a strong emphasis on growth hormone sales [6] - Plans for mergers and acquisitions are centered on the health industry, with a focus on innovative development and market expansion [7][8] - The long-acting growth hormone is expected to gain market acceptance as it progresses through clinical phases [8]